Watson’s Uracyst pilot study for interstitial cystitis fails to demonstrate efficacy endpoints

Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that the U.S. pilot study evaluating Uracyst® (sodium chondroitin sulfate solution 2.0%) for the treatment of interstitial cystitis did not meet predefined efficacy endpoints.

"Unfortunately, the results of the pilot study failed to demonstrate efficacy despite numerical separation of response between Uracyst® and placebo on certain measurements," said Fred Wilkinson, Watson's Executive Vice President, Global Brands. "We will work with Stellar Pharmaceuticals Inc. to further evaluate the response and assist in determining any next steps, but at this time we do not plan to allocate any additional resources to further pursue this development program.  While regrettable, our decision will permit Watson to strategically refocus development resources on other product candidates in our development portfolio."